TY - JOUR
T1 - Lipopolysaccharide induces CXCL2/macrophage inflammatory protein-2 gene expression in enterocytes via NF-κB activation
T2 - Independence from endogenous TNF-α and platelet-activating factor
AU - De Plaen, Isabelle G.
AU - Han, Xin Bing
AU - Liu, Xueli
AU - Hsueh, Wei
AU - Ghosh, Sankar
AU - May, Michael J.
PY - 2006/6
Y1 - 2006/6
N2 - CXCL2 (macrophage inflammatory protein-2 (MIP-2)), a critical chemokine for neutrophils, has been shown to be produced in the rat intestine in response to platelet-activating factor (PAF) and to mediate intestinal inflammation and injury. The intestinal epithelium, constantly exposed to bacterial products, is the first line of defence against micro-organisms. It has been reported that enterocytes produce proinflammatory mediators, including tumour necrosis factor (TNF) and PAF, and we showed that lipopolysaccharide (LPS) and TNF activate nuclear factor (NF)-κB in enterocytes. However, it remains elusive whether enterocytes release CXCL2 in response to LPS and TNF via a NF-κB- dependent pathway and whether this involves the endogenous production of TNF and PAF. In this study, we found that TNF and LPS markedly induced CXCL2 gene expression in IEC-6 cells, TNF within 30 min, peaking at 45 min, while LPS more slowly, peaking after 2 hr. TNF- and LPS- induced CXCL2 gene expression and protein release were completely blocked by pyrrolidine dithiocarbamate (PDTC) and helenalin, two potent NF-κB inhibitors. NEMO-binding domain peptide, a specific inhibitor of inhibitor protein κB kinase (IKK) activation, a major upstream kinase mediating NF-κB activation, significantly blocked CXCL2 gene expression and protein release induced by LPS. WEB2170 (PAF antagonist) and anti-TNF antibodies had no effect on LPS-induced CXCL2 expression. In conclusion, CXCL2 gene is expressed in enterocytes in response to both TNF and LPS. LPS-induced CXCL2 expression is dependent on NF-κB activation via the IKK pathway. The effect of LPS is independent of endogenous TNF and PAF.
AB - CXCL2 (macrophage inflammatory protein-2 (MIP-2)), a critical chemokine for neutrophils, has been shown to be produced in the rat intestine in response to platelet-activating factor (PAF) and to mediate intestinal inflammation and injury. The intestinal epithelium, constantly exposed to bacterial products, is the first line of defence against micro-organisms. It has been reported that enterocytes produce proinflammatory mediators, including tumour necrosis factor (TNF) and PAF, and we showed that lipopolysaccharide (LPS) and TNF activate nuclear factor (NF)-κB in enterocytes. However, it remains elusive whether enterocytes release CXCL2 in response to LPS and TNF via a NF-κB- dependent pathway and whether this involves the endogenous production of TNF and PAF. In this study, we found that TNF and LPS markedly induced CXCL2 gene expression in IEC-6 cells, TNF within 30 min, peaking at 45 min, while LPS more slowly, peaking after 2 hr. TNF- and LPS- induced CXCL2 gene expression and protein release were completely blocked by pyrrolidine dithiocarbamate (PDTC) and helenalin, two potent NF-κB inhibitors. NEMO-binding domain peptide, a specific inhibitor of inhibitor protein κB kinase (IKK) activation, a major upstream kinase mediating NF-κB activation, significantly blocked CXCL2 gene expression and protein release induced by LPS. WEB2170 (PAF antagonist) and anti-TNF antibodies had no effect on LPS-induced CXCL2 expression. In conclusion, CXCL2 gene is expressed in enterocytes in response to both TNF and LPS. LPS-induced CXCL2 expression is dependent on NF-κB activation via the IKK pathway. The effect of LPS is independent of endogenous TNF and PAF.
KW - CXCL2 (MIP-2)
KW - Chemokine
KW - Intestine
KW - LPS
KW - Nuclear factor-κB
KW - TNF
UR - http://www.scopus.com/inward/record.url?scp=33646560337&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646560337&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2567.2006.02344.x
DO - 10.1111/j.1365-2567.2006.02344.x
M3 - Article
C2 - 16771850
AN - SCOPUS:33646560337
SN - 0019-2805
VL - 118
SP - 153
EP - 163
JO - Immunology
JF - Immunology
IS - 2
ER -